Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 8	FEB 10	COMPENDEX reloaded and enhanced
NEWS 9	FEB 11	WTEXTILES reloaded and enhanced
NEWS 10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 24	APR 07	STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

```
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:03:12 ON 22 APR 2009

=> file registry
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 10:03:25 ON 22 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 APR 2009  HIGHEST RN 1137276-53-9
DICTIONARY FILE UPDATES:  20 APR 2009  HIGHEST RN 1137276-53-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10706328_updated.str
```



```
chain nodes :
7  12  13  29  30  31  32  33  34  35
ring nodes :
1  2  3  4  5  6  8  9  10  11  14  15  16  17  18  19  20  21  22  23  24  25  26
27  28
chain bonds :
1-32  2-31  3-30  4-7  8-13  9-14  10-12  19-33  20-34  21-23  22-35  26-29
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-8  6-11  8-9  9-10  10-11  14-15  14-18  15-16
16-17  16-19  17-18  17-22  19-20  20-21  21-22  23-24  23-28  24-25  25-26  26-27
27-28
exact/norm bonds :
5-8  6-11  8-9  8-13  9-10  10-11  10-12  14-15  14-18  15-16  17-18  21-23  23-24
23-28  24-25  25-26  26-27  27-28
exact bonds :
1-32  2-31  3-30  4-7  9-14  19-33  20-34  22-35  26-29
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-19  17-22  19-20  20-21  21-22


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:Atom  9:Atom  10:Atom
11:Atom  12:CLASS  13:CLASS  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:Atom  28:Atom
29:CLASS  30:CLASS  31:CLASS  32:CLASS  33:CLASS  34:CLASS  35:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 exa
SAMPLE SEARCH INITIATED 10:03:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       17 TO ITERATE

100.0% PROCESSED       17 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          93 TO      587
PROJECTED ANSWERS:              0 TO        0

L2            0 SEA EXA SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:03:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1381 TO ITERATE

100.0% PROCESSED     1381 ITERATIONS                               31 ANSWERS
SEARCH TIME: 00.00.01

L3           31 SEA SSS FUL L1

=> s l1
SAMPLE SEARCH INITIATED 10:04:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       65 TO ITERATE

100.0% PROCESSED       65 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         817 TO     1783
```

PROJECTED ANSWERS: 1 TO 80

L4 1 SEA SSS SAM L1

=> d 14

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 915769-50-5 REGISTRY
ED Entered STN: 18 Dec 2006
CN Propanoic acid, 2-hydroxy-, compd. with
    4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-
    quinolinone, hydrate (1:1:1) (CA INDEX NAME)
MF C21 H21 F N6 O . C3 H6 O3 . H2 O
SR CA
LC STN Files: CA, CAPLUS, IMSRESEARCH, PHAR, PROUSDDR, SYNTHLINE,
      TOXCENTER, USAN

    CM 1

    CRN 405169-16-6
    CMF C21 H21 F N6 O



    CM 2

    CRN 50-21-5
    CMF C3 H6 O3



              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus wpids uspatfull
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 188.41 188.63

FILE 'MEDLINE' ENTERED AT 10:04:35 ON 22 APR 2009

FILE 'CAPLUS' ENTERED AT 10:04:35 ON 22 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'WPIDS' ENTERED AT 10:04:35 ON 22 APR 2009

```
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 10:04:35 ON 22 APR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l3
SAMPLE SEARCH INITIATED 10:04:40 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:             0 TO        0
PROJECTED ANSWERS:                0 TO        0

L5          92 L3

=> s l5 and (?cancer? or ?tumor? or ?tumour? or ?neoplasm?)
L6          79 L5 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)

=> s l6 and (pd<20031107 or prd<20031107)
'20031107' NOT A VALID FIELD CODE
   1 FILES SEARCHED...
   3 FILES SEARCHED...
L7          23 L6 AND (PD<20031107 OR PRD<20031107)

=> s l7 and ("PDGFR" or "c-kit" or "FLT-3")
   3 FILES SEARCHED...
L8          12 L7 AND ("PDGFR" OR "C-KIT" OR "FLT-3")

=> d l8 1-12 ibib, abs, hitstr

L8   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2005:1242789  CAPLUS
DOCUMENT NUMBER:          143:477969
TITLE:                    Preparation of benzimidazole quinolinones for
                          inhibiting FGFR3 and treating multiple myeloma
INVENTOR(S):              Cai, Shaopei; Chou, Joyce; Harwood, Eric; Heise, Carla
                          C.; Machajewski, Timothy D.; Ryckman, David; Shang,
                          Xiao; Wiesmann, Marion; Zhu, Shuguang
PATENT ASSIGNEE(S):       Chiron Corporation, USA
SOURCE:                   U.S. Pat. Appl. Publ., 239 pp., Cont.-in-part of U.S.
                          Ser. No. 644,055.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   7
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    --------------------     --------
     US 20050261307       A1    20051124    US 2004-983174           20041105 <--
     US 20040092535       A1    20040513    US 2003-644055           20030819 <--
     US 7470709           B2    20081230
     CN 1692112           A     20051102    CN 2003-824565           20030819 <--
     US 20050203101       A1    20050915    US 2004-839793           20040505 <--
PRIORITY APPLN. INFO.:                      US 2002-405729P     P    20020823 <--
                                            US 2002-426107P     P    20021113 <--
                                            US 2002-426226P     P    20021113 <--
                                            US 2002-426282P     P    20021113 <--
```

US 2002-428210P	P	20021121	<--
US 2003-460327P	P	20030403	<--
US 2003-460328P	P	20030403	<--
US 2003-460493P	P	20030403	<--
US 2003-478916P	P	20030616	<--
US 2003-484048P	P	20030701	<--
US 2003-644055	A2	20030819	<--
US 2003-517915P	P	20031107	
US 2003-526425P	P	20031202	
US 2003-526426P	P	20031202	
US 2004-546017P	P	20040219	

OTHER SOURCE(S): MARPAT 143:477969

GI



I



II

AB The title compds. I [A, B, C, and D = C, N; R1-R3 = H, halo, CN, NO2, etc.; R4 = H, alkyl; R5-R8 = H, halo, CN, NO2, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H], useful for inhibiting fibroblast growth factor receptor 3 or treating a biol. condition mediated by fibroblast growth factor receptor 3, were prepared E.g., a multi-step synthesis of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one (II), starting from 5-chloro-2-nitroaniline and 1-methylpiperazine, was given. The majority of the exemplary compds. I displayed an IC50 of less than 10 μM with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1ε, Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFR.alpha., and PDGFR.beta.. In addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFR.alpha., and PDGFR.beta. with IC50 values of less than 1 μM. The mentioned above compound II was tested in various tests and showed significant antiproliferative activity. II inhibited FGFR3 receptor

phosphorylation and ERK phosphorylation in multiple myeloma cell lines with activating FGFR3 mutations.

IT 405169-16-6P 668434-24-0P 692737-80-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazole quinolinones for inhibiting FGFR3 and treating multiple myeloma)

RN 405169-16-6 CAPLUS
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 668434-24-0 CAPLUS
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-4-oxido-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 692737-80-7 CAPLUS
CN Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (1:1) (CA INDEX NAME)

CM 1

CRN 405169-16-6
CMF C21 H21 F N6 O



CM 2

CRN 50-21-5
CMF C3 H6 O3

L8 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1223876 CAPLUS
DOCUMENT NUMBER: 143:477966
TITLE: Preparation of benzimidazole quinolinones for inhibiting a checkpoint kinase 1 and their use in combination therapy for cancer
INVENTOR(S): Gesner, Thomas G.; Barsanti, Paul A.; Harrison, Stephen D.; Ni, Zhi-Jie; Brammeier, Nathan M.; Zhou, Yasheen; Le, Vincent P.
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 249 pp., Cont.-in-part of U.S. Ser. No. 644,055.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20050256157	A1	20051117	US 2005-41191		20050121	<--
US 20040092535	A1	20040513	US 2003-644055		20030819	<--
US 7470709	B2	20081230				
CN 1692112	A	20051102	CN 2003-824565		20030819	<--
US 20050203101	A1	20050915	US 2004-839793		20040505	<--
PRIORITY APPLN. INFO.:			US 2002-405729P	P	20020823	<--
			US 2002-426107P	P	20021113	<--
			US 2002-426226P	P	20021113	<--
			US 2002-426282P	P	20021113	<--
			US 2002-428210P	P	20021121	<--
			US 2003-460327P	P	20030403	<--
			US 2003-460328P	P	20030403	<--
			US 2003-460493P	P	20030403	<--
			US 2003-478916P	P	20030616	<--
			US 2003-484048P	P	20030701	<--
			US 2003-644055	A2	20030819	<--
			US 2004-538984P	P	20040123	

OTHER SOURCE(S): CASREACT 143:477966; MARPAT 143:477966
GI



I

AB The title compds. [I; A, B, C, D = C, N; R1 = H, halo, CN, NO2, etc.; R2, R3 = H, halo, NO2, CN, etc.; R4 = H, (un)substituted alkyl; R5, R8 = H, (un)substituted alkyl, alkenyl, heterocyclyl; or R5 may be absent if A = N; or R8 may be absent if D = N; R6, R7 = H, halo, NO2, CN, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H; or R9 and R10 join together to form one or more rings, each having 5-7 members], useful for inhibiting checkpoint kinase 1, inducing cell cycle progression, and increasing apoptosis in cells, were prepared E.g., a multi-step synthesis of 4-amino-3-(benzimidazol-2-yl)-6-(4-methylpiperazinyl)hydroquinolin-2-one, was given. The compds. I were tested against various kinases. Two of the prepared compds. I, 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)-6-chloroquinolin-2-(1H)-one and 6-chloro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-4-[(piperidin-2-ylmethyl)amino]quinolin-2(1H)-one, were found to be potent inhibitors of CHK1 with IC50 of 0.32 nM and 0.63 nM, resp. The majority of the exemplary compds. I displayed an IC50 of less than 10 μM with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1ε, Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFR.alpha., and PDGFR.beta.. In addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFR.alpha., and PDGFR.beta. with IC50 values of less than 1 μM. The compds. I may be used to prepare pharmaceutical compns. and may be used in conjunction with DNA damaging agents.

IT 405169-16-6P 668434-24-0P 692737-80-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazole quinolinones for inhibiting a checkpoint kinase 1 and their use in combination therapy for cancer)

RN 405169-16-6 CAPLUS

CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 668434-24-0 CAPLUS
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-4-oxido-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 692737-80-7 CAPLUS
CN Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (1:1) (CA INDEX NAME)

CM 1

CRN 405169-16-6
CMF C21 H21 F N6 O



CM 2

CRN 50-21-5
CMF C3 H6 O3

L8 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:99470 CAPLUS
DOCUMENT NUMBER: 142:197889
TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases
INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2005009961	A2	20050203	WO 2004-US23500	20040722	<--
WO 2005009961	A3	20050331			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004259760	A1	20050203	AU 2004-259760	20040722	<--
CA 2532865	A1	20050203	CA 2004-2532865	20040722	<--
US 20050038080	A1	20050217	US 2004-895985	20040722	<--
EP 1663978	A2	20060607	EP 2004-786091	20040722	<--
EP 1663978	B1	20071128			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
BR 2004012219	A	20060822	BR 2004-12219	20040722	<--
CN 1856469	A	20061101	CN 2004-80021091	20040722	<--
JP 2006528196	T	20061214	JP 2006-521221	20040722	<--
ES 2297490	T3	20080501	ES 2004-786091	20040722	<--
KR 2006052866	A	20060519	KR 2006-701558	20060123	<--
MX 2006000860	A	20060720	MX 2006-860	20060123	<--
IN 2006DN00402	A	20070824	IN 2006-DN402	20060123	<--
NO 2006000870	A	20060407	NO 2006-870	20060222	<--
PRIORITY APPLN. INFO.:			US 2003-489102P P	20030723	<--
			US 2004-540326P P	20040202	
			WO 2004-US23500 W	20040722	

OTHER SOURCE(S): CASREACT 142:197889
GI



I

AB Title compound I is prepared I and salts thereof is prepared in several steps from 3-fluoro-4-nitrophenol, 4-chloro-N-methylpyridine-2-carboxamide and 4-chloro-3-(trifluoromethyl)phenylisocyanate. I inhibits PDGFR tyrosine kinase with IC50 = 83 nM. I is useful for the treatment of, e.g., inflammation and as an antiproliferative agent.

IT 692737-80-7, CHIR 258
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph urea for treatment of raf, VEGFR, PDGFR, p38 and flt -3 kinase-mediated diseases)

RN 692737-80-7 CAPLUS

CN Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (1:1) (CA INDEX NAME)

CM 1

CRN 405169-16-6
CMF C21 H21 F N6 O



CM 2

CRN 50-21-5
CMF C3 H6 O3



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:428803 CAPLUS
DOCUMENT NUMBER: 141:1211
TITLE: Methods of treating cancer with a methylpiperazinyl benzimidazolyl quinolinone and related methods
INVENTOR(S): Machajewski, Timothy D.; Hannah, Alison; Harwood, Eric; Haroldsen, Peter; Heise, Carla C.; Samara, Emil; Shang, Xiao; Vora, Jayesh; Zhu, Shuguang
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043389	A2	20040527	WO 2003-US35806	20031112 <--
WO 2004043389	A3	20040805		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2501932	A1	20040527	CA 2003-2501932	20031112	<--
AU 2003290699	A1	20040603	AU 2003-290699	20031112	<--
US 20040220196	A1	20041104	US 2003-706328	20031112	<--
EP 1565187	A2	20050824	EP 2003-783281	20031112	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003016229	A	20051004	BR 2003-16229	20031112	<--
CN 1711088	A	20051221	CN 2003-80103178	20031112	<--
CN 100377709	C	20080402			
JP 2006511616	T	20060406	JP 2005-507133	20031112	<--
NZ 539425	A	20071130	NZ 2003-539425	20031112	<--
SG 148864	A1	20090129	SG 2007-3449	20031112	<--
MX 2005004754	A	20050802	MX 2005-4754	20050503	<--
IN 2005KN00793	A	20060303	IN 2005-KN793	20050503	<--
NO 2005002760	A	20050720	NO 2005-2760	20050607	<--

PRIORITY APPLN. INFO.:	US 2002-426107P	P	20021113	<--
	US 2002-426204P	P	20021113	<--
	US 2002-426282P	P	20021113	<--
	US 2003-460328P	P	20030403	<--
	US 2003-460369P	P	20030403	<--
	US 2003-460493P	P	20030403	<--
	US 2003-517915P	P	20031107	
	WO 2003-US35806	W	20031112	

AB Methods of treating cancer using 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one (I) are provided. In particular, the methods are effective for the treatment of solid tumors or leukemias, including prostate, colorectal, breast, multiple myeloma, pancreatic, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, or myelo-proliferative disease. Further provided are methods of measuring the amount of I and determining a metabolic profile therefore. The growth of both the KM12L4a and MV4;11 xenografts in mice were potently inhibited by I in vivo.

IT 405169-16-6
RL: ANT (Analyte); BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(cancer treatment with methylpiperazinyl benzimidazolyl quinolinone and related methods)

RN 405169-16-6 CAPLUS

CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



IT 405169-16-6D, salts, tautomers
RL: ANT (Analyte); BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(cancer treatment with methylpiperazinyl benzimidazolyl quinolinone and related methods)
RN 405169-16-6 CAPLUS
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



IT 692737-80-7P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cancer treatment with methylpiperazinyl benzimidazolyl quinolinone and related methods)
RN 692737-80-7 CAPLUS
CN Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (1:1) (CA INDEX NAME)

CM 1

CRN 405169-16-6
CMF C21 H21 F N6 O



CM 2

CRN 50-21-5
CMF C3 H6 O3



IT 692737-81-8

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(distribution in tissues; cancer treatment with
methylpiperazinyl benzimidazolyl quinolinone and related methods)
RN 692737-81-8 CAPLUS
CN 2(1H)-Quinolinone-4-14C, 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



IT 668434-24-0P
RL: ANT (Analyte); BSU (Biological study, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation)
(metabolite; cancer treatment with methylpiperazinyl
benzimidazolyl quinolinone and related methods)
RN 668434-24-0 CAPLUS
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-4-oxido-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



L8 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:182836 CAPLUS
DOCUMENT NUMBER: 140:235711
TITLE: Preparation of benzimidazole quinolinones for inhibiting a serine/threonine kinase
INVENTOR(S): Barsanti, Paul A.; Bussiere, Dirksen; Harrison, Stephen D.; Heise, Carla C.; Jansen, Johanna M.; Jazan, Elisa; Machajewski, Timothy D.; Mcbride, Christopher; McCrea, William R.; Ng, Simon; Ni, Zhi-Jie; Pecchi, Sabina; Pfister, Keith; Ramurthy, Savithri; Renhowe, Paul A.; Shafer, Cynthia M.; Silver, Joel B.; Wagman, Allan; Weismann, Marion
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 570 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2004018419	A2	20040304	WO 2003-US25990		20030819	<--
WO 2004018419	A3	20040603				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
CA 2496164	A1	20040304	CA 2003-2496164		20030819	<--
AU 2003288899	A1	20040311	AU 2003-288899		20030819	<--
EP 1539754	A2	20050615	EP 2003-781286		20030819	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
BR 2003013743	A	20050705	BR 2003-13743		20030819	<--
CN 1692112	A	20051102	CN 2003-824565		20030819	<--
JP 2006503919	T	20060202	JP 2005-501762		20030819	<--
IN 2005KN00484	A	20060106	IN 2005-KN484		20050323	<--
PRIORITY APPLN. INFO.:			US 2002-405729P	P	20020823	<--
			US 2002-426107P	P	20021113	<--
			US 2002-426226P	P	20021113	<--
			US 2002-426282P	P	20021113	<--
			US 2002-428210P	P	20021121	<--
			US 2003-460327P	P	20030403	<--
			US 2003-460328P	P	20030403	<--
			US 2003-460493P	P	20030403	<--
			US 2003-478916P	P	20030616	<--
			US 2003-484048P	P	20030701	<--
			WO 2003-US25990	W	20030819	<--

OTHER SOURCE(S): MARPAT 140:235711

GI



I



II

AB The title compds. [I and II; A, B, C, and D = C, N; W, X, Y and Z = C, N and at least one of W, X, Y, and Z = N; R1-R8 = H, halo, CN, NO2, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H; or NR9R10 = 5-7 membered ring], useful for inhibiting various enzymes and treating various conditions, were prepared E.g., a multi-step synthesis of 4-amino-3-(benzimidazol-2-yl)-6-(4-methylpiperazinyl)hydroquinolin-2-one, was given. The majority of the exemplary compds. I displayed an IC50 of less than 10 μM with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1ε, Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFR.alpha., and PDGFR β. In addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFR.alpha., and PDGFR.beta. with IC50 values of less than 1 μM.

IT 405169-16-6P 668434-24-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazole quinolinones for inhibiting a serine/threonine kinase)

RN 405169-16-6 CAPLUS

CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 668434-24-0 CAPLUS
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-4-oxido-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



L8 ANSWER 6 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2007:83463 USPATFULL
TITLE: Use of tyrosine kinase inhibitor to treat diabetes
INVENTOR(S): Hagerkvist, Robert Per, Hoganasgatan 7B, Uppsala, SWEDEN 75330
Welsh, Nils Richard, Uppsala, SWEDEN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20070072932	A1	20070329	
APPLICATION INFO.:	US 2004-556984	A1	20040526	(10)
	WO 2004-EP5679		20040526	
			20060622	PCT 371 date

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 2003-12086	20030527	<--
	GB 2004-2682	20040206	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1-10
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 857
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of a c-Abl-, PDGF-R-, or c-kit- tyrosine kinase inhibitor, e.g. 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of diabetes, e.g. type I diabetes, type II diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 405169-16-6, CHIR 258
(c-abl-, PDGFR-, or c-kit-tyrosine kinase inhibitor for treatment of diabetes)
RN 405169-16-6 USPATFULL
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



L8 ANSWER 7 OF 12 USPATFULL on STN

ACCESSION NUMBER:	2005:299638 USPATFULL
TITLE:	Inhibition of FGFR3 and treatment of multiple myeloma
INVENTOR(S):	Cai, Shaopei, Seattle, WA, UNITED STATES Chou, Joyce, El Cerrito, CA, UNITED STATES Harwood, Eric, Seattle, WA, UNITED STATES Heise, Carla C., Benicia, CA, UNITED STATES Machajewski, Timothy D., Martinez, CA, UNITED STATES Ryckman, David, Bellevue, WA, UNITED STATES Shang, Xiao, Bellevue, WA, UNITED STATES Wiesmann, Marion, Brisbane, CA, UNITED STATES Zhu, Shuguang, Shoreline, WA, UNITED STATES
PATENT ASSIGNEE(S):	Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20050261307	A1	20051124	
APPLICATION INFO.:	US 2004-983174	A1	20041105 (10)	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-644055, filed on 19 Aug 2003, PENDING			

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-517915P	20031107 (60)	
	US 2003-526426P	20031202 (60)	
	US 2003-526425P	20031202 (60)	
	US 2004-546017P	20040219 (60)	
	US 2002-405729P	20020823 (60)	<--
	US 2002-426107P	20021113 (60)	<--
	US 2002-426226P	20021113 (60)	<--
	US 2002-426282P	20021113 (60)	<--
	US 2002-428210P	20021121 (60)	<--
	US 2003-460328P	20030403 (60)	<--
	US 2003-460493P	20030403 (60)	<--
	US 2003-460327P	20030403 (60)	<--
	US 2003-478916P	20030616 (60)	<--
	US 2003-484048P	20030701 (60)	<--

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
NUMBER OF CLAIMS:	28

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 17221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 405169-16-6P 668434-24-0P 692737-80-7P
(preparation of benzimidazole quinolinones for inhibiting FGFR3 and treating multiple myeloma)
RN 405169-16-6 USPATFULL
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 668434-24-0 USPATFULL
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-4-oxido-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 692737-80-7 USPATFULL
CN Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (1:1) (CA INDEX NAME)

CM 1

CRN 405169-16-6
CMF C21 H21 F N6 O



CM 2

CRN 50-21-5
CMF C3 H6 O3



L8 ANSWER 8 OF 12 USPATFULL on STN

ACCESSION NUMBER:	2005:293608 USPATFULL
TITLE:	Combination therapy with CHK1 inhibitors
INVENTOR(S):	Gesner, Thomas G., Kensington, CA, UNITED STATES Barsanti, Paul A., Pleasant Hill, CA, UNITED STATES Harrison, Stephen D., Albany, CA, UNITED STATES Ni, Zhi-Jie, Fremont, CA, UNITED STATES Brammeier, Nathan M., Walnut Creek, CA, UNITED STATES Zhou, Yasheen, Moraga, CA, UNITED STATES Le, Vincent P., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S):	CHIRON CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20050256157	A1	20051117	
APPLICATION INFO.:	US 2005-41191	A1	20050121 (11)	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-644055, filed on 19 Aug 2003, PENDING			

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2004-538984P	20040123 (60)	
	US 2002-405729P	20020823 (60)	<--
	US 2002-426282P	20021113 (60)	<--
	US 2002-426107P	20021113 (60)	<--
	US 2002-426226P	20021113 (60)	<--
	US 2002-428210P	20021121 (60)	<--
	US 2003-460493P	20030403 (60)	<--
	US 2003-460328P	20030403 (60)	<--
	US 2003-460327P	20030403 (60)	<--
	US 2003-478916P	20030616 (60)	<--
	US 2003-484048P	20030701 (60)	<--

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
NUMBER OF CLAIMS:	32
EXEMPLARY CLAIM:	1

NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 16679
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 405169-16-6P 668434-24-0P 692737-80-7P
(preparation of benzimidazole quinolinones for inhibiting a checkpoint kinase 1 and their use in combination therapy for cancer)
RN 405169-16-6 USPATFULL
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 668434-24-0 USPATFULL
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-4-oxido-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 692737-80-7 USPATFULL
CN Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (1:1) (CA INDEX NAME)

CM 1

CRN 405169-16-6
CMF C21 H21 F N6 O



CM 2

CRN 50-21-5
CMF C3 H6 O3

L8 ANSWER 9 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2005:234162 USPATFULL
TITLE: Benzimidazole quinolinones and uses thereof
INVENTOR(S): Barsanti, Paul A., Pleasant Hill, CA, UNITED STATES
Bussiere, Dirksen, San Leandro, CA, UNITED STATES
Harrison, Stephen D., Albany, CA, UNITED STATES
Heise, Carla C., Benicia, CA, UNITED STATES
Jansen, Johanna M., San Francisco, CA, UNITED STATES
Jazan, Elisa, Berkeley, CA, UNITED STATES
Machajewski, Timothy D., Martinez, CA, UNITED STATES
McBride, Christopher, Oakland, CA, UNITED STATES
McCrea, William R. JR., Berkeley, CA, UNITED STATES
Ng, Simon, Walnut Creek, CA, UNITED STATES
Ni, Zhi-Jie, Fremont, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
Pfister, Keith B., San Ramon, CA, UNITED STATES
Ramurthy, Savithri, Walnut Creek, CA, UNITED STATES
Renhowe, Paul A., Danville, CA, UNITED STATES
Shafer, Cynthia M., El Sobrante, CA, UNITED STATES
Silver, Joel B., Santa Cruz, CA, UNITED STATES
Wagman, Allan S., Belmont, CA, UNITED STATES
Wiesmann, Marion, Brisbane, CA, UNITED STATES
Wayman, Kelly, San Rafael, CA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20050203101	A1	20050915	
APPLICATION INFO.:	US 2004-839793	A1	20040505 (10)	
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-644055, filed on 19 Aug 2003, PENDING			
	NUMBER	DATE		
PRIORITY INFORMATION:	US 2002-405729P	20020823 (60)		<--
	US 2002-426107P	20021113 (60)		<--
	US 2002-426226P	20021113 (60)		<--
	US 2002-426282P	20021113 (60)		<--

	US 2002-428210P	20021121 (60)	<--
	US 2003-460328P	20030403 (60)	<--
	US 2003-460493P	20030403 (60)	<--
	US 2003-460327P	20030403 (60)	<--
	US 2003-478916P	20030616 (60)	<--
	US 2003-484048P	20030701 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 14866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of treating cancer include contacting a cancer cell with 4-amino-5-fluoro-3-(5-piperazin-1-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one, 4-amino-5-fluoro-3-[5-(4-methyl-4-oxidopiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable salts of the tautomers thereof, or a mixture thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 405169-16-6P 668434-24-0P
(preparation of benzimidazole quinolinones for inhibiting a serine/threonine kinase)
RN 405169-16-6 USPATFULL
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 668434-24-0 USPATFULL
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-4-oxido-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



L8 ANSWER 10 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2005:44347 USPATFULL
TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

INVENTOR(S): Boyer, Stephen, Hilden, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Bethany, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Wilhelm, Scott, Orange, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050038080	A1	20050217
APPLICATION INFO.:	US 2004-895985	A1	20040722 (10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-489102P	20030723 (60)	<--
	US 2004-540326P	20040202 (60)	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 2492
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of Formula (I): ##STR1##

salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by raf, VEGFR, PDGFR, p38 and flt-3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 804551-71-1, CHIR 258
(combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases)
RN 804551-71-1 USPATFULL

L8 ANSWER 11 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2004:280895 USPATFULL
TITLE: Methods of treating cancer and related methods
INVENTOR(S): Hannah, Alison, Sebastopol, CA, UNITED STATES
Harwood, Eric, Seattle, WA, UNITED STATES
Haroldsen, Peter, Pacifica, CA, UNITED STATES
Heise, Carla, Benecia, CA, UNITED STATES
Machajewski, Timothy, Martinez, CA, UNITED STATES
Samara, Emil, Danville, CA, UNITED STATES
Shang, Xiao, Bellevue, WA, UNITED STATES
Vora, Jayesh, Martinez, CA, UNITED STATES
Zhu, Shuguang, Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040220196	A1	20041104
APPLICATION INFO.:	US 2003-706328	A1	20031112 (10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-460369P	20030403 (60)	<--
	US 2003-460493P	20030403 (60)	<--
	US 2003-460328P	20030403 (60)	<--

	US 2002-426204P	20021113 (60)	<--
	US 2002-426282P	20021113 (60)	<--
	US 2002-426107P	20021113 (60)	<--
	US 2003-517915P	20031107 (60)	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 2045
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating cancer using 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one are provided. In particular, the methods are effective for the treatment of solid tumors or leukemias, including prostate, colorectal, breast, multiple myeloma, pancreatic, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, or myelo-proliferative disease. Further provided are methods of measuring the amount of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one and determining a metabolic profile therefore.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 405169-16-6P 668434-24-0P
(preparation of benzimidazole quinolinones for inhibiting a serine/threonine kinase)
RN 405169-16-6 USPATFULL
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 668434-24-0 USPATFULL
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-4-oxido-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



L8 ANSWER 12 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2004:121119 USPATFULL
TITLE: Benzimidazole quinolinones and uses thereof
INVENTOR(S): Barsanti, Paul A., Walnut Creek, CA, UNITED STATES
Bussiere, Dirksen, San Leandro, CA, UNITED STATES
Harrison, Stephen D., Albany, CA, UNITED STATES
Heise, Carla C., Benicia, CA, UNITED STATES
Jansen, Johanna M., San Francisco, CA, UNITED STATES
Jazan, Elisa, Richmond, CA, UNITED STATES
Michajewski, Timothy D., Martinez, CA, UNITED STATES
McBride, Christopher, Oakland, CA, UNITED STATES
McCrea, William R., JR., Berkeley, CA, UNITED STATES
Ng, Simon, Walnut Creek, CA, UNITED STATES
Ni, Zhi-Jie, Fremont, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
Pfister, Keith B., San Ramon, CA, UNITED STATES
Ramurthy, Savithri, Walnut Creek, CA, UNITED STATES
Renhowe, Paul A., Danville, CA, UNITED STATES
Shafer, Cynthia M., El Sobrante, CA, UNITED STATES
Silver, Joel B., Concord, NH, UNITED STATES
Wagman, Allan S., Belmont, CA, UNITED STATES
Wiesmann, Marion, Brisbane, CA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20040092535	A1	20040513	
	US 7470709	B2	20081230	
APPLICATION INFO.:	US 2003-644055	A1	20030819	(10)

	NUMBER	DATE		
PRIORITY INFORMATION:	US 2002-405729P	20020823	(60)	<--
	US 2002-426107P	20021113	(60)	<--
	US 2002-426226P	20021113	(60)	<--
	US 2002-426282P	20021113	(60)	<--
	US 2002-428210P	20021121	(60)	<--
	US 2003-460328P	20030403	(60)	<--
	US 2003-460493P	20030403	(60)	<--
	US 2003-460327P	20030403	(60)	<--
	US 2003-478916P	20030616	(60)	<--
	US 2003-484048P	20030701	(60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 18050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 405169-16-6P 668434-24-0P
(preparation of benzimidazole quinolinones for inhibiting a serine/threonine

kinase)
RN 405169-16-6 USPATFULL
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 668434-24-0 USPATFULL
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-4-oxido-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 10:03:12 ON 22 APR 2009)

FILE 'REGISTRY' ENTERED AT 10:03:25 ON 22 APR 2009
L1 STRUCTURE UPLOADED
L2 0 S L1 EXA
L3 31 S L1 FULL
L4 1 S L1

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:04:35 ON 22 APR 2009
L5 92 S L3
L6 79 S L5 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)
L7 23 S L6 AND (PD<20031107 OR PRD<20031107)
L8 12 S L7 AND ("PDGFR" OR "C-KIT" OR "FLT-3")

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	199.25	387.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.10	-4.10

STN INTERNATIONAL LOGOFF AT 10:17:17 ON 22 APR 2009